1. Home
  2. NAKA vs ACIU Comparison

NAKA vs ACIU Comparison

Compare NAKA & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kindly MD Inc.

NAKA

Kindly MD Inc.

HOLD

Current Price

$0.49

Market Cap

265.2M

Sector

N/A

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$3.43

Market Cap

213.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAKA
ACIU
Founded
2019
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
265.2M
213.3M
IPO Year
2024
2016

Fundamental Metrics

Financial Performance
Metric
NAKA
ACIU
Price
$0.49
$3.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$4.50
$10.00
AVG Volume (30 Days)
12.6M
1.5M
Earning Date
11-19-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,980,278.00
$5,482,957.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2,774.04
$644.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$1.43
52 Week High
$34.77
$4.00

Technical Indicators

Market Signals
Indicator
NAKA
ACIU
Relative Strength Index (RSI) 51.48 60.00
Support Level $0.35 $3.09
Resistance Level $0.52 $3.30
Average True Range (ATR) 0.04 0.22
MACD 0.03 0.05
Stochastic Oscillator 84.85 66.86

Price Performance

Historical Comparison
NAKA
ACIU

About NAKA Kindly MD Inc.

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: